NCT05816746 2023-05-09
Decitabine and Anti-PD-1 in R/R DLBCL
Chinese PLA General Hospital
Phase 2 Unknown
Clinical Trials
20 trialsNCT05362942 2022-05-05
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2 Unknown
NCT05265962 2022-03-04
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05137886 2021-12-17
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04752527 2021-11-15
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03467178 2021-09-05
MITO29
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT03080766 2021-04-28
The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype
The University of Hong Kong
Phase 2 Unknown
NCT04025593 2020-11-19
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04541277 2020-09-09
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
Chinese PLA General Hospital
Phase 2 Unknown
NCT04514081 2020-08-18
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
Chinese PLA General Hospital
Phase 2 Unknown
NCT04233294 2020-08-14
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
NCT04279379 2020-05-07
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 2 Unknown
NCT03417427 2020-04-27
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04353479 2020-04-20
Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT04049344 2019-08-08
Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT03250962 2019-04-01
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
NCT03771222 2018-12-13
Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies
Chinese PLA General Hospital
Phase 2 Unknown
NCT03381781 2018-01-04
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
Ruijin Hospital
Phase 2 Unknown
NCT03356080 2017-11-29
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
Shanghai Tong Ren Hospital
Phase 2 Unknown
NCT01133886 2010-09-03
DEC-MDS
King's College London
Phase 2 Unknown